ConductScience.org, home

Comparison · NCT04497142-5a7f6896

Perampanel + Electrocorticography vs Standard of Care + Electrocorticography: Seizure-freedom

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Perampanel + Electrocorticography vs Standard of Care + Electrocorticography: Seizure-freedom. Trial comparisons, record NCT04497142-5a7f6896. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04497142-5a7f6896

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1430.02570.513wilson
Risk in group 20.50.150.85wilson
Risk difference, group 1 minus group 2-0.357-0.7260.152newcombe hybrid score
Risk ratio, group 1 over group 20.2860.03632.25log
Odds ratio, group 1 over group 20.1670.009312.98log
Number needed to treat, for one fewer participant with the outcome on Perampanel + Electrocorticography than on Standard of Care + Electrocorticography2.8from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Perampanel + Electrocorticography
Perampanel 6mg on day prior to resection, 4mg pre-op prior to resection, and 4mg daily until PD or up to 12 months. Intraoperative ECoG with 20 contact subdural grid performed for analysis of high frequency oscillation (80-500 Hz) rate.
17OG000
Group 2Standard of Care + ElectrocorticographyLevetiracetam peri-operatively per standard of care. Intraoperative ECoG with 20 contact subdural grid performed for analysis of high frequency oscillation (80-500 Hz) rate.24OG001

Outcome

Type
SECONDARY
Title
Seizure-freedom
Description
Seizure-free rates were assessed from the time of initial glioma resection to radiographic tumor progression or up to a maximum of 12 months.
Time frame
From time of initial surgery to PD or up to 12 months
Population

Source ClinicalTrials.gov

Trial

Title
Effect of Perampanel on Peritumoral Hyperexcitability in HGG
NCT number
NCT04497142
Phases
PHASE1, PHASE2
Conditions
Glioma, Malignant, Surgery, Seizures
Interventions
Perampanel, Standard of Care
Lead sponsor
Dana-Farber Cancer Institute
Results first posted
2024-08-05

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04497142-5a7f6896